Hydroxyamphetamine

DB09352ApprovedSmall moleculeAdrenergic Agonists

Hydroxyamphetamine is an indirectly acting sympathomimetic agent producing mydriasis for diagnostic purposes. Hydroxyamphetamine is a derivative of amphetamines.

Mechanism: Hydroxyamphetamine hydrobromide is an indirect acting sympathomimetic agent which causes the release of norepinephrine from adrenergic nerve terminals, resulting in mydriasis.
Curator reviewed
Primary indication: Mydriatic agent (eye pupil dilatation) for diagnosis of ophthalmic nerve lesions.Curator reviewed · 1 structured indication
Formula / weight: C₉H₁₃NO · 151.2056 g/mol (avg)
First approval: United States, 1992
Also known as: 4-hydroxyamphetamine · dl-p-hydroxyamphetamine · Hydroxyamfetamine · p-hydroxyamphetamine
Code names: NSC-170995
Brand names: Paremyd

Resolves to

Compound

UNIIFQR280JW2NCAS103-86-6ChEMBLCHEMBL1546ChEBI103855PubChem3651

Clinical / RWD

RxNorm7839

Structure

InChIKeyGIKNHHRFLCDOEU-UHFFFAOYSA-NSMILESCC(N)CC1=CC=C(O)C=C1

Targets

Q96RJ0TAAR1P14416DRD2P21917DRD4

What you can answer from here — as of September 23, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

57Drug interactionsStructured to mechanism, not free text

1Structured indicationCondition, population, route and combination as fields, not prose

2ContraindicationsEach with its own population and attribute set

1Marketed productAcross 1 country and 1 labeller

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Hydroxyamphetamine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In